Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis

Table 1

Dosing schedule, nadir counts and reported complications in Cases 1, 2 and 3.

Case 1
Course 1
	Ifosfamide dose/m^2∗	Nadir WBC (K/uL) [ANC (K/uL)]	Nadir PLT (K/uL)	Complication
Cycle 1	2 g/m^2	6.7 [4.7]	81
Cycle 2	3 g/m^2	3 [2.9]	53
Cycle 3	3 g/m^2	2.6 [2.3]	5	Thrombocytopenia NCI grade 4
Cycle 4	2 g/m^2	7 [4.5]	50
Cycle 5	2 g/m^2	6.4 [5.4]	44
Cycle 6	2 g/m^2	7 [5.3]	30
14-Month interval
Course 2
Cycle 1	2 g/m^2	8.9 [6.8]	35
Cycle 2	3 g/m^2	5 [4.6]	55
Cycle 3	3.6 g/m^2	2.2 [1.3]	48
Cycle 4	4 g/m^2	0.79 [0.26]	17	Epistaxis NCI grade 1
Case 2
Cycle 1	1.5 g/m^2	4.3 [3.3]	125
Cycle 2	1.8 g/m^2	3.8 [2.7]	115
Cycle 3	2 g/m^2	8 [7.4]	95
Case 3
Cycle 1	1.5 g/m^2	8.9 [6.3]	106	Cellulitis NCI grade 2
Cycle 2	1.8 g/m^2	13.7 [8.4]	334	Cellulitis NCI grade 2

^∗Note: For Cases 1 and 3, this represents the total dose of ifosfamide, split over 2 consecutive days
Case 2 received a single dose of ifosfamide per cycle.